Mylan N.V. Improves in the Third Quarter Thanks to International Sales

Despite being a global drugmaker, the fortunes of Mylan N.V. (NASDAQ:MYL) are tightly linked to the U.S. market. Continued headwinds in the U.S. for generic drugs caused Mylan to slash its full-year outlook for 2018 in August. This move, though, lowered the bar for the company as it entered the third quarter.